Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

Clinical trial NCT07223411 · RECRUITING

Trial details

NCT number: NCT07223411
Sponsor: John Kirkwood
Status: RECRUITING
Study type: OBSERVATIONAL

Locally Advanced Melanoma

Start date: 2025-11-19
Primary completion: 2028-11-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.